VVT MedTSXV:VVTM +7.14%6 3-Year RORE % is 0.00 as of Sep. 2025. GuruFocus rates TSXV:VVTM with a GF Score™ of 6/100. The stock has 4 warning signs investors should review. Among 781 Medical Devices & Instruments companies, VVT Med ranks worse than 128040.85% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
VVT Med does not have enough data to calculate 3-Year RORE %.
VVT Med (TSXV:VVTM) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
VVT Med 3-Year RORE % Related Terms
VVT Med 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for VVT Med's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:VVTM vs ABT, SYK, MDT: 3-Year RORE % Comparison
For the Medical Devices subindustry, VVT Med's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VVT Med 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, VVT Med's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where VVT Med's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2025 and 3-year before.
VVT Med (TSXV:VVTM) has a 3-Year RORE % of 0.00 as of Sep. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on VVT Med and its competitors. According to the industry distribution chart, VVT Med ranks #999999 out of 781 companies in the Medical Devices & Instruments industry.
Is VVT Med's 3-Year RORE % too high?
VVT Med's current 3-Year RORE % is 0.00. Based on the distribution chart, VVT Med ranks #999999 out of 781 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, VVT Med has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does VVT Med's 3-Year RORE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, VVT Med ranks #999999 out of 781 companies for 3-Year RORE %. This places VVT Med in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on VVT Med and its competitors. VVT Med's current 3-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VVT Med stock overvalued right now?
VVT Med (TSXV:VVTM) has a current 3-Year RORE % of 0.00. The current 3-Year RORE % is 0.00. VVT Med's overall GF Score™ is 6/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For VVT Med (TSXV:VVTM), the current 3-Year RORE % is 0.00 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
VVT Med Inc is a medical device company, focused on developing and commercializing a range of minimally invasive technologies for treating varicose veins. VVT's research and development activities are based in Israel. The company proudly boasts three products within its portfolio that have achieved commercial production status and are currently available in the market. These products have undergone meticulous design processes, obtaining regulatory approvals across multiple countries.
6GF Score
Get the complete analysis for TSXV:VVTM
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:VVTM has been successfully added to your 
